Thomas W. Jarrett, MD, Author at Grand Rounds in Urology

Thomas W. Jarrett, MD

Brady Urological Institute and Department of Urology at Johns Hopkins School of Medicine

Baltimore, Maryland

Dr. Thomas W. Jarrett, Chief of Urology, National Capital Region, at the Brady Urological Institute and Department of Urology at Johns Hopkins School of Medicine, has an expertise in minimally invasive surgery, including laparoscopic, robotic, ureteroscopic, percutaneous and image-guided therapies. Specifically, he has an expertise in percutaneous renal surgery, laparoscopic partial and radical nephrectomy, kidney stones, urinary tract reconstruction and kidney cancer.

Dr. Jarrett earned his medical degree from Emory University School of Medicine, where he also completed his internship. He completed a residency in urology at New York Hospital, followed by a visiting fellowship in urology and ultrasonography in Salzburg, Austria. Dr. Jarrett completed his fellowship in endo-urology at Long Island Jewish Medical Center. He has previously served as the chief of the division of endourology and laparoscopy at the Johns Hopkins Hospital and the chief of the division of urology at Johns Hopkins Bayview Medical Center.

Dr. Jarrett has contributed to various publications and presentations on urology, earning him first prize in the World Congress of Endourology essay contest and the Faculty Research Award at Long Island Jewish Medical Center. He has editorial appointments at the Journal of Endourology and the Journal of Laparoendoscopic and Advanced Surgical Techniques.

Disclosures:

Talks by Thomas W. Jarrett, MD

Life Expectancy as It Relates to the Treatment of Urologic Cancers

Posted by Thomas W. Jarrett, MD | Jul 2024

Thomas W. Jarrett, MD, discusses the impact of life expectancy on urologic cancer treatment and management in the United States. He begins by highlighting outdated life expectancy models and the importance of assessing life expectancy prior to exploring treatment options.

Dr. Jarrett then discusses the traditional methods of assessing life expectancy and their failure to account for patient comorbidities. He lists the most significant comorbidities which impact life expectancy according to their hazard score.

Dr. Jarrett then addresses overall trends in life expectancy in the United States. He notes that life expectancy sharply decreased during COVID-19 and that the United States has yet to recover compared to European life expectancy trends.

Dr. Jarrett concludes by illustrating the influence of perceived life expectancy on urologic cancer management and outcomes. He discusses the impact of life expectancy on treatment options for urothelial cancer, testicular cancer, renal cancer, and prostate cancer.

Thomas W. Jarrett, MD

Brady Urological Institute and Department of Urology at Johns Hopkins School of Medicine

Baltimore, Maryland

Talks by Thomas W. Jarrett, MD

Life Expectancy as It Relates to the Treatment of Urologic Cancers

Join the GRU Community

You have Successfully Subscribed!